In the Claims

Claim 1 (Currently amended).

An amended recombinant cell (ARC) comprising at least one heterologous gene, said at least one heterologous gene encoding a chemokine or a cytokine.

Claim 2 (Currently amended).

The ARC according to claim 1, wherein said ARC further comprises at least one additional ~~the~~ heterologous gene that encodes IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-15, Il-16, Il-18, IL-23, IL-24, erythropoietin, G-CSF, M-CSF, platelet derived growth factor (PDGF), MSF, FLT-3 ligand, EGF, fibroblast growth factor (FGF); aFGF (FGF-1); bFGF (FGF-2); FGF-3; FGF-4; FGF-5; FGF-6; FGF-7; insulin-like growth factor 1 (IGF-1); IGF-2; vascular endothelial growth factor (VEGF); IFN-γ; IFN-α; IFN-β; leukemia inhibitory factor (LIF); ciliary neurotrophic factor (CNTF); oncostatin M; stem cell factor (SCF); TGF-α; TGF-β1; TGF-β2; a chemokine selected from the group consisting of BCA-1/BLC-1, BRAK/Kec, CXCL16, CXCR3, ENA-78/LIX, Eotaxin-1, Eotaxin-2/MPIF-2, Exodus-2/SLC, Fractalkine/Neurotactin, GROalpha/MGSA, HCC-1, I-TAC, Lymphotactin/ATAC/SCM, MCP-1/MCAF, MCP-3, MCP-4, MDC/STCP-1, ABCD-1, MIP-1α, MIP-1β, MIP-2α/GROβ, MIP-3α/Exodus/LARC, MIP-3β/Exodus-3/ELC, MIP-4/PARC/DC-CK1, PF-4, RANTES, SDF1α, TARC, and TECK; or ~~those cytokines or chemokines~~ a cytokine or chemokine as provided in Tables 1, 8, and 9.

Claim 3 (Currently amended).

The ARC according to ~~claim 2~~claim 1, ~~wherein the~~ wherein said at least one heterologous gene encodes IFN-γ.

Claim 4 (Original).

The ARC according to claim 3, wherein said IFN-γ is bovine, avian, fish, or human.

Claim 5 (Original).

The ARC according to claim 4, wherein said IFN-γ is bovine.

Claim 6 (Original).

The ARC according to claim 4, wherein said avian IFN-γ is chicken IFN-γ.

Claim 7 (Currently amended).

The ARC according to claim 2, wherein ~~the ARC further comprises a heterologous gene encoding~~ said at least one additional heterologous gene encodes IFN-α.

Claim 8 (Original).

The ARC according claim 1, wherein said cell is a microbial cell selected from the group consisting of Gram positive organisms, Gram negative organisms, yeast, and fungi.

Claim 9 (Original).

The ARC according to claim 8, wherein the microbial cell is *Pseudomonas fluorescens*.

Claim 10 (Original).

The ARC according to claim 1, further comprising a carrier.

Claim 11 (Withdrawn).

A method of inducing or accelerating an immune response in an individual to an antigen or immunogen comprising the step of administering, to an individual:

amended recombinant cells (ARCs) comprising at least one heterologous gene encoding a chemokine or a cytokine; or

a composition comprising amended recombinant cells (ARCs) comprising at least one heterologous gene encoding a chemokine or a cytokine.

Claim 12 (Withdrawn).

The method according to claim 11, wherein said method further comprises the administration of an antigen of interest.

Claim 13 (Withdrawn).

The method according to claim 12, further comprising the administration of lipopolysaccharide (LPS).

Claim 14 (Withdrawn).

The method according to claim 11, wherein said heterologous gene encodes IFN-γ.

Claim 15 (Withdrawn).

The method according to claim 14, wherein said IFN-γ is bovine, avian, fish, or human.

Claim 16 (Withdrawn).

The method according to claim 15, wherein said IFN-γ is bovine.

Claim 17 (Withdrawn).

The method according to claim 15, wherein said avian IFN-γ is chicken IFN-γ.

Claim 18 (Withdrawn).

The method according to claim 11, wherein the ARCs co-express at least one antigen of interest.

Claim 19-31 (Canceled).

Claim 32 (Currently amended).

A method of making an amended recombinant cell (ARC) comprising the steps of:

a) introducing at least one heterologous gene encoding a cytokine into a cell ~~and, optionally, a chemokine into a cell~~;

b) growing said cell in a nutrient medium;

c) harvesting said cells; and

d) inactivating or fixing said cells.

Claim 33 (Currently amended).

The method according to claim 32, said method comprising introducing at least one additional ~~wherein the~~ heterologous gene into said cell, said at least one additional heterologous gene ~~encodes~~ encoding IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-15, Il-16, Il-18, IL-23, IL-24, erythropoietin, G-CSF, M-CSF, platelet derived growth factor (PDGF), MSF, FLT-3 ligand, EGF, fibroblast growth factor (FGF); aFGF (FGF-1); bFGF (FGF-2); FGF-3; FGF-4; FGF-5; FGF-6; FGF-7; insulin-like growth factor 1 (IGF-1); IGF-2; vascular endothelial growth factor (VEGF); IFN-γ;-IFN-α; IFN-β; leukemia inhibitory factor (LIF); ciliary neurotrophic factor (CNTF); oncostatin M; stem cell factor (SCF); TGF-α; TGF-β1; TGF-β2; a chemokine selected from the group consisting of BCA-1/BLC-1, BRAK/Kec, CXCL16, CXCR3, ENA-78/LIX, Eotaxin-1, Eotaxin-2/MPIF-2, Exodus-2/SLC, Fractalkine/Neurotactin, GROalpha/MGSA, HCC-1, I-TAC, Lymphotactin/ATAC/SCM, MCP-1/MCAF, MCP-3, MCP-4, MDC/STCP-1, ABCD-1, MIP-1α, MIP-1β, MIP-2α/GROβ, MIP-3α/Exodus/LARC, MIP-3β/Exodus-3/ELC, MIP-4/PARC/DC-CK1, PF-4, RANTES, SDF1α, TARC, and TECK; or ~~those cytokines or chemokines~~ a cytokine or chemokine as provided in Tables 1, 8 and 9.

Claim 34 (Currently amended).

The method according to ~~claim 33~~claim 32, wherein ~~the heterologous~~ said at least one heterologous gene encodes IFN-γ.

Claim 35 (Original).

The method according to claim 34, wherein said IFN-γ is bovine, avian, fish, or human.

Claim 36 (Original).

The method according to claim 35, wherein said IFN-γ is bovine.

Claim 37 (Original).

The method according to claim 35, wherein said avian IFN-γ is chicken IFN-γ.

Claim 38 (Currently amended).

The method according to claim 33, wherein ~~the ARC further comprises a heterologous gene encoding~~ said at least one additional heterologous gene encodes IFN-α.

Claim 39 (New).

The method according to claim 34, said method comprising introducing at least one additional heterologous gene encoding a chemokine into said cell.

Claim 40 (New).

The method according to claim 34, wherein said at least one additional heterologous gene encodes IFN-α.

Claim 41 (New).

The ARC according to claim 3, wherein said ARC further comprises at least one additional heterologous gene that encodes IFN-α.

Claim 42 (New).

The ARC according to claim 9, wherein said *Pseudomonas fluorescens* cell comprises at least one heterologous gene that encodes IFN-γ.

Claim 43 (New).

The ARC according to claim 42, wherein said IFN-γ is bovine, avian, fish, or human.

Claim 44 (New).

The ARC according to claim 43, wherein said IFN-γ is bovine.

Claim 45 (New).

The ARC according to claim 43, wherein said avian IFN-γ is chicken IFN-γ.

Claim 46 (New).

The ARC according to claim 42, wherein said ARC further comprises at least one additional heterologous gene.

Claim 47 (New).

The ARC according to claim 46, wherein said at least one additional heterologous gene. encodes IFN-α.